A citation-based method for searching scientific literature

Stephen M Ansell, Monique C Minnema, Peter Johnson, John M Timmerman, Philippe Armand, Margaret A Shipp, Scott J Rodig, Azra H Ligon, Margaretha G M Roemer, Nishitha Reddy, Jonathon B Cohen, Sarit Assouline, Michelle Poon, Manish Sharma, Kazunobu Kato, Selda Samakoglu, Anne Sumbul, Andrew Grigg. J Clin Oncol 2019
Times Cited: 181







List of co-cited articles
1016 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.
Alexander M Lesokhin, Stephen M Ansell, Philippe Armand, Emma C Scott, Ahmad Halwani, Martin Gutierrez, Michael M Millenson, Adam D Cohen, Stephen J Schuster, Daniel Lebovic,[...]. J Clin Oncol 2016
687
42

Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes.
Bjoern Chapuy, Chip Stewart, Andrew J Dunford, Jaegil Kim, Atanas Kamburov, Robert A Redd, Mike S Lawrence, Margaretha G M Roemer, Amy J Li, Marita Ziepert,[...]. Nat Med 2018
754
35

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
Stephen M Ansell, Alexander M Lesokhin, Ivan Borrello, Ahmad Halwani, Emma C Scott, Martin Gutierrez, Stephen J Schuster, Michael M Millenson, Deepika Cattry, Gordon J Freeman,[...]. N Engl J Med 2015
34

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.
Roland Schmitz, George W Wright, Da Wei Huang, Calvin A Johnson, James D Phelan, James Q Wang, Sandrine Roulland, Monica Kasbekar, Ryan M Young, Arthur L Shaffer,[...]. N Engl J Med 2018
881
30

Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.
Philippe Armand, Scott Rodig, Vladimir Melnichenko, Catherine Thieblemont, Kamal Bouabdallah, Gayane Tumyan, Muhit Özcan, Sergio Portino, Laura Fogliatto, Maria D Caballero,[...]. J Clin Oncol 2019
121
26

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.
A A Alizadeh, M B Eisen, R E Davis, C Ma, I S Lossos, A Rosenwald, J C Boldrick, H Sabet, T Tran, X Yu,[...]. Nature 2000
23

Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.
Junichi Kiyasu, Hiroaki Miyoshi, Akie Hirata, Fumiko Arakawa, Ayako Ichikawa, Daisuke Niino, Yasuo Sugita, Yuji Yufu, Ilseung Choi, Yasunobu Abe,[...]. Blood 2015
316
22

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Stephen J Schuster, Michael R Bishop, Constantine S Tam, Edmund K Waller, Peter Borchmann, Joseph P McGuirk, Ulrich Jäger, Samantha Jaglowski, Charalambos Andreadis, Jason R Westin,[...]. N Engl J Med 2019
21

Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.
Anupama Reddy, Jenny Zhang, Nicholas S Davis, Andrea B Moffitt, Cassandra L Love, Alexander Waldrop, Sirpa Leppa, Annika Pasanen, Leo Meriranta, Marja-Liisa Karjalainen-Lindsberg,[...]. Cell 2017
561
19

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
Michael R Green, Stefano Monti, Scott J Rodig, Przemyslaw Juszczynski, Treeve Currie, Evan O'Donnell, Bjoern Chapuy, Kunihiko Takeyama, Donna Neuberg, Todd R Golub,[...]. Blood 2010
844
19

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
Robert Chen, Pier Luigi Zinzani, Michelle A Fanale, Philippe Armand, Nathalie A Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P Vassilakopoulos,[...]. J Clin Oncol 2017
624
19

PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype.
James Godfrey, Sravya Tumuluru, Riyue Bao, Michael Leukam, Girish Venkataraman, John Phillip, Carrie Fitzpatrick, James McElherne, Brendan W MacNabb, Robert Orlowski,[...]. Blood 2019
59
32

Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma.
Madhavi Challa-Malladi, Yen K Lieu, Olivia Califano, Antony B Holmes, Govind Bhagat, Vundavalli V Murty, David Dominguez-Sola, Laura Pasqualucci, Riccardo Dalla-Favera. Cancer Cell 2011
293
18

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
Sattva S Neelapu, Frederick L Locke, Nancy L Bartlett, Lazaros J Lekakis, David B Miklos, Caron A Jacobson, Ira Braunschweig, Olalekan O Oluwole, Tanya Siddiqi, Yi Lin,[...]. N Engl J Med 2017
18

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
Anas Younes, Armando Santoro, Margaret Shipp, Pier Luigi Zinzani, John M Timmerman, Stephen Ansell, Philippe Armand, Michelle Fanale, Voravit Ratanatharathorn, John Kuruvilla,[...]. Lancet Oncol 2016
646
18

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.
Ranjana Advani, Ian Flinn, Leslie Popplewell, Andres Forero, Nancy L Bartlett, Nilanjan Ghosh, Justin Kline, Mark Roschewski, Ann LaCasce, Graham P Collins,[...]. N Engl J Med 2018
522
18

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study.
Michael Crump, Sattva S Neelapu, Umar Farooq, Eric Van Den Neste, John Kuruvilla, Jason Westin, Brian K Link, Annette Hay, James R Cerhan, Liting Zhu,[...]. Blood 2017
717
18

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.
Andreas Rosenwald, George Wright, Wing C Chan, Joseph M Connors, Elias Campo, Richard I Fisher, Randy D Gascoyne, H Konrad Muller-Hermelink, Erlend B Smeland, Jena M Giltnane,[...]. N Engl J Med 2002
17

Stromal gene signatures in large-B-cell lymphomas.
G Lenz, G Wright, S S Dave, W Xiao, J Powell, H Zhao, W Xu, B Tan, N Goldschmidt, J Iqbal,[...]. N Engl J Med 2008
17

A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications.
George W Wright, Da Wei Huang, James D Phelan, Zana A Coulibaly, Sandrine Roulland, Ryan M Young, James Q Wang, Roland Schmitz, Ryan D Morin, Jeffrey Tang,[...]. Cancer Cell 2020
270
17

The 2016 revision of the World Health Organization classification of lymphoid neoplasms.
Steven H Swerdlow, Elias Campo, Stefano A Pileri, Nancy Lee Harris, Harald Stein, Reiner Siebert, Ranjana Advani, Michele Ghielmini, Gilles A Salles, Andrew D Zelenetz,[...]. Blood 2016
16

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Bertrand Coiffier, Eric Lepage, Josette Briere, Raoul Herbrecht, Hervé Tilly, Reda Bouabdallah, Pierre Morel, Eric Van Den Neste, Gilles Salles, Philippe Gaulard,[...]. N Engl J Med 2002
15

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
Philippe Armand, Andreas Engert, Anas Younes, Michelle Fanale, Armando Santoro, Pier Luigi Zinzani, John M Timmerman, Graham P Collins, Radhakrishnan Ramchandren, Jonathon B Cohen,[...]. J Clin Oncol 2018
372
15

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.
Philippe Armand, Margaret A Shipp, Vincent Ribrag, Jean-Marie Michot, Pier Luigi Zinzani, John Kuruvilla, Ellen S Snyder, Alejandro D Ricart, Arun Balakumaran, Shelonitda Rose,[...]. J Clin Oncol 2016
463
15

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.
Margaretha G M Roemer, Ranjana H Advani, Azra H Ligon, Yasodha Natkunam, Robert A Redd, Heather Homer, Courtney F Connelly, Heather H Sun, Sarah E Daadi, Gordon J Freeman,[...]. J Clin Oncol 2016
483
15

The immune landscape and response to immune checkpoint blockade therapy in lymphoma.
Justin Kline, James Godfrey, Stephen M Ansell. Blood 2020
74
20

Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.
Christopher D Carey, Daniel Gusenleitner, Mikel Lipschitz, Margaretha G M Roemer, Edward C Stack, Evisa Gjini, Xihao Hu, Robert Redd, Gordon J Freeman, Donna Neuberg,[...]. Blood 2017
192
15

PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation.
Matthew J Frigault, Philippe Armand, Robert A Redd, Erin Jeter, Reid W Merryman, Kimberly C Coleman, Alex F Herrera, Parastoo Dahi, Yago Nieto, Ann S LaCasce,[...]. Blood Adv 2020
28
53

Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy.
Stephen D Smith, Brian G Till, Mazyar S Shadman, Ryan C Lynch, Andrew J Cowan, Qian V Wu, Jenna Voutsinas, Heather A Rasmussen, Katherine Blue, Chaitra S Ujjani,[...]. Br J Haematol 2020
39
38

PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.
Zijun Y Xu-Monette, Jianfeng Zhou, Ken H Young. Blood 2018
215
14

The tumour microenvironment in B cell lymphomas.
David W Scott, Randy D Gascoyne. Nat Rev Cancer 2014
311
14

Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.
Stephen M Ansell, Sara A Hurvitz, Patricia A Koenig, Betsy R LaPlant, Brian F Kabat, Donna Fernando, Thomas M Habermann, David J Inwards, Meena Verma, Reiko Yamada,[...]. Clin Cancer Res 2009
231
14

PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.
Benjamin J Chen, Bjoern Chapuy, Jing Ouyang, Heather H Sun, Margaretha G M Roemer, Mina L Xu, Hongbo Yu, Christopher D M Fletcher, Gordon J Freeman, Margaret A Shipp,[...]. Clin Cancer Res 2013
582
14

Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study.
Pier Luigi Zinzani, Armando Santoro, Giuseppe Gritti, Pauline Brice, Paul M Barr, John Kuruvilla, David Cunningham, Justin Kline, Nathalie A Johnson, Neha Mehta-Shah,[...]. J Clin Oncol 2019
65
21

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.
Wyndham H Wilson, Ryan M Young, Roland Schmitz, Yandan Yang, Stefania Pittaluga, George Wright, Chih-Jian Lih, P Mickey Williams, Arthur L Shaffer, John Gerecitano,[...]. Nat Med 2015
713
14

Targetable genetic features of primary testicular and primary central nervous system lymphomas.
Bjoern Chapuy, Margaretha G M Roemer, Chip Stewart, Yuxiang Tan, Ryan P Abo, Liye Zhang, Andrew J Dunford, David M Meredith, Aaron R Thorner, Ekaterina S Jordanova,[...]. Blood 2016
305
13

Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma.
Pier Luigi Zinzani, Vincent Ribrag, Craig H Moskowitz, Jean-Marie Michot, John Kuruvilla, Arun Balakumaran, Yayan Zhang, Sabine Chlosta, Margaret A Shipp, Philippe Armand. Blood 2017
202
13

Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
Daisuke Ennishi, Aixiang Jiang, Merrill Boyle, Brett Collinge, Bruno M Grande, Susana Ben-Neriah, Christopher Rushton, Jeffrey Tang, Nicole Thomas, Graham W Slack,[...]. J Clin Oncol 2019
153
13

Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas.
Konstantinos Georgiou, Longyun Chen, Mattias Berglund, Weicheng Ren, Noel F C C de Miranda, Susana Lisboa, Marco Fangazio, Shida Zhu, Yong Hou, Kui Wu,[...]. Blood 2016
131
13

Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.
Andreas Viardot, Marie-Elisabeth Goebeler, Georg Hess, Svenja Neumann, Michael Pfreundschuh, Nicole Adrian, Florian Zettl, Martin Libicher, Cyrus Sayehli, Julia Stieglmaier,[...]. Blood 2016
217
13

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087.
Robert Chen, Pier Luigi Zinzani, Hun Ju Lee, Philippe Armand, Nathalie A Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P Vassilakopoulos,[...]. Blood 2019
160
13

Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.
Jeremy S Abramson, M Lia Palomba, Leo I Gordon, Matthew A Lunning, Michael Wang, Jon Arnason, Amitkumar Mehta, Enkhtsetseg Purev, David G Maloney, Charalambos Andreadis,[...]. Lancet 2020
591
13

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
Gilles Salles, Johannes Duell, Eva González Barca, Olivier Tournilhac, Wojciech Jurczak, Anna Marina Liberati, Zsolt Nagy, Aleš Obr, Gianluca Gaidano, Marc André,[...]. Lancet Oncol 2020
186
13

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.
Christine P Hans, Dennis D Weisenburger, Timothy C Greiner, Randy D Gascoyne, Jan Delabie, German Ott, H Konrad Müller-Hermelink, Elias Campo, Rita M Braziel, Elaine S Jaffe,[...]. Blood 2004
12

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.
Wei Ding, Betsy R LaPlant, Timothy G Call, Sameer A Parikh, Jose F Leis, Rong He, Tait D Shanafelt, Sutapa Sinha, Jennifer Le-Rademacher, Andrew L Feldman,[...]. Blood 2017
242
12

Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition.
Daisuke Ennishi, Katsuyoshi Takata, Wendy Béguelin, Gerben Duns, Anja Mottok, Pedro Farinha, Ali Bashashati, Saeed Saberi, Merrill Boyle, Barbara Meissner,[...]. Cancer Discov 2019
137
12

Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.
Michael R Green, Scott Rodig, Przemyslaw Juszczynski, Jing Ouyang, Papiya Sinha, Evan O'Donnell, Donna Neuberg, Margaret A Shipp. Clin Cancer Res 2012
476
12

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
Anas Younes, Joshua Brody, Cecilia Carpio, Armando Lopez-Guillermo, Dina Ben-Yehuda, Burhan Ferhanoglu, Arnon Nagler, Muhit Ozcan, Irit Avivi, Francesc Bosch,[...]. Lancet Haematol 2019
102
12

PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.
Lakshmi Nayak, Fabio M Iwamoto, Ann LaCasce, Srinivasan Mukundan, Margaretha G M Roemer, Bjoern Chapuy, Philippe Armand, Scott J Rodig, Margaret A Shipp. Blood 2017
251
12

Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma.
Philippe Armand, Ann Janssens, Giuseppe Gritti, John Radford, John Timmerman, Antonio Pinto, Santiago Mercadal Vilchez, Peter Johnson, David Cunningham, John P Leonard,[...]. Blood 2021
38
31


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.